The **22** TB high Burden countries - WHO

**TB Burden, Uganda** (WHO 2009 Report):
- Ranked No. 16
- All forms of TB per year: 42,000 cases (NTRL 2009)
- Mortality from all forms of TB: 29,000
- High HIV prevalence (6.4% POPn and 50% in TB patients)
Case notification rate reported by Uganda
(total number per 100,000 population reported in 2009)

- All forms of TB: 134.3
- New Smear positive cases: 70.0
- New Smear negative cases: 37.3
- Retreatment cases: 12.2

- Low case notification of sm-ve (ratio of 2 : 1 – Pos:Neg)
- This may be due to High HIV burden
Diagnosis of smear –ve TB

- The NTLP recommends a CXR after 2 negative smears in PTB suspects

- CXRs are in HCV while microscopy in HCIII and HCII

- Hence multiple visits and long delays before diagnosis of smear –ve PTB, patients likely to give up
Xpert MTB/RIF implementation in Uganda

Sites for Scale-up Evidence:
2. Luwero: District level HC IV

Total tests in one year:
1800 (both sites together, estimated for one year load)

Implementation:
Routine NTLP programmatic

NTLP policy guidance:
For TB/HIV populations, and MDR-TB suspects

Reporting and recording:
As per NTLP recording and reporting; GeneXpert report provided to clinicians

Technology transfer/Full equip/Cartridge support by:
FIND, Geneva/Uganda

Supervision and monitoring:
NTLP/NTRL, and FIND

Uganda with select sites
Xpert MTB/RIF indication

- HIV (+) individuals suspected of having PTB
- INDIVIDUALS SUSPECTED OF MDR-TB
  - TB CAT I TREATMENT FAILURE, RELAPSE or DEFAULT
- HIV Negative/Unknown, Sputum Smear Negative- but suspected of PTB (no chest x-ray available/or abnormal chest x-ray)
- SERIOUSLY ILL PATIENTS SUSPECTED OF PTB
- Individuals at risk of MDR-TB (diagnosed of TB, or suspected of having TB)

PTB- Pulmonary Tuberculosis
MDR-TB- Multidrug resistant TB (resistance to rifampicin and isoniazid)
Status

- NTLP/NTRL identified Xpert MTB/RIF sites after initial assessment of needs and on-site visits, with FIND support.
- Site Priority
  - TB/HIV congregated setting (PRISON)
  - District level HC IV- without Chest X-ray facility
- EQUIPMENT imported (Jan), installed at two sites (Feb/March)
- Equipment validated based on QC Panel of four sputum samples (frozen) with known Culture and DST results (MGIT)
- Internal controls of equipment validated per each test
- Two Laboratory technicians per site were trained
- Standard operating procedures developed per each site based on generic document
- Clinicians (four per site) oriented, on referral activities and result interpretation
Implementation of *XpertMTB/RIF* test (Scale-up for evidence) Murchison Bay Prison Hospital, Laboratory, Luzira, Uganda Establishment of *GeneXpert* lab (Mar 2011)
GeneXpert lab in Murchison Bay Prison Lab, Luzira/Kampala, Uganda